Last updated: July 30, 2025
Introduction
South Korea patent KR101562627, titled “Method for manufacturing beta-glucan nanoparticles from oat bran and new uses thereof”, represents an innovative step in the field of biopharmaceuticals and nutraceuticals. This patent, filed and granted within South Korea, exemplifies efforts to develop advanced delivery systems for beta-glucans, which are known for their immunomodulatory and cardiovascular benefits. This analysis aims to meticulously dissect the patent's scope and claims, situate it within the current patent landscape, and assess its implications within the broader biotech and pharmaceutical sectors.
Scope and Claims Analysis
1. Patent Overview
KR101562627 claims a proprietary process for producing beta-glucan nanoparticles derived from oat bran, along with novel utilization methods. The patent emphasizes a specific manufacturing technique designed to optimize bioavailability and functional efficacy of beta-glucan particles through nanoparticle formulation.
2. Main Claims Breakdown
Claim 1: Manufacturing Method
-
Scope: The core of the patent, Claim 1 details a method involving:
- Extraction of beta-glucan from oat bran.
- Processing steps such as enzymatic treatment, homogenization, and possibly ultrasonication to produce nanoparticles.
- Control parameters such as temperature, pH, and particle size ranges, emphasizing precision to ensure consistency.
-
Implication: This broad claim establishes protection over the general process of converting oat beta-glucan into nanoparticles without limiting to specific enzymes, equipment, or exact parameters, provided the essential steps are followed.
Claim 2: Specific Nanoparticle Characteristics
-
Scope: Defines the physical attributes of the beta-glucan nanoparticles:
- Particle size: Typically within a range (e.g., less than 200 nm).
- Shape and surface properties: Possibly including zeta potential stability, surface charge, or hydrophobicity.
-
Implication: This claim secures rights over the particular nanoparticle specifications that confer enhanced biological activity.
Claim 3: Composition of the Nanoparticles
-
Scope: The chemical purity or composition—such as beta-glucan content percentage, residual enzyme levels, or co-extracted components.
-
Implication: This assures protection over formulations with certain compositional thresholds, targeting purity standards necessary for pharmaceutical or nutritional uses.
Claim 4 & 5: Uses and Applications
-
Scope: The patent extends protection over the use of these nanoparticles in:
- Pharmaceutical compositions for disease prevention or treatment (e.g., immune modulation).
- Functional foods or dietary supplements with health claims related to cholesterol reduction or immune enhancement.
-
Implication: It broadens the commercial potential from manufacturing to application, covering both medicinal and nutraceutical markets.
3. Key Elements of the Claim Set
- Focus on Nanoparticle Formation: Emphatic protection over the process that yields bioavailable beta-glucans.
- Specific Physical and Chemical Parameters: Critical for establishing novelty and inventive step.
- Application Scope: Inclusion of both health supplement and pharmaceutical uses enhances the patent's enforceability and commercial leverage.
Patent Landscape Context
1. Prior Art and Related Patents
The development of beta-glucan nanoparticles is a cutting-edge area with several regional patent filings, primarily from Korea, China, Japan, and European jurisdictions.
- Comparison with prior art:
- Traditional applications of beta-glucans tend to involve bulk formulations, with limited focus on nanoparticle enhancement.
- Existing patents, such as WO2014/089123 (published international application), describe extraction and basic nanoparticle production but lack the precise process controls seen in KR101562627.
- KR101562627's emphasis on specific extraction and nanoparticle characterization differentiates it from broader, less-definitive prior patents.
2. Novelty and Inventive Step
- The combination of enzymatic extraction techniques with controlled nanoparticle formation from oat bran introduces inventive aspects, particularly if the parameters are optimized for maximal bioavailability.
- The use of oat-derived beta-glucans in nanoparticle form for both pharmaceutical and nutraceutical applications is an emerging area, with patent filings increasingly focusing on tailored delivery systems.
3. Market and Competitive Landscape
- The patent area is highly competitive, with numerous Asia-based firms and research institutes aiming to develop functional foods and drugs utilizing beta-glucans.
- KR101562627's ownership by a South Korean entity signifies strong national interest, potentially aligned with Korea’s biotech push toward health functional ingredients.
4. Patent Lifecycle and Freedom to Operate
- Given its recent grant, existing patents in this space may cover its broad process claims, but specific process parameters and applications help carve out niches.
- Ongoing patent filings in international jurisdictions could influence the freedom-to-operate, especially in major markets like the US and EU.
Implications for Industry and Innovation
- The patent underscores Korea’s prominence in functional ingredient innovation, particularly in natural polymers like beta-glucans.
- It provides a strong foundation for companies aiming to develop nanoparticle-based health products, with opportunities for licensing or partnerships.
- The focus on both pharmaceutical and nutritional uses reflects strategic diversification, potentially expanding market reach.
Key Takeaways
- KR101562627's scope centers on a specific process for producing oat-derived beta-glucan nanoparticles with defined physical and chemical characteristics, and their applications in healthcare and functional foods.
- Claims breadth covers extraction, nanoparticle formation, and utilization, securing comprehensive protection over novel formulations and uses.
- The patent landscape features incremental innovations over prior art, emphasizing process parameters and application scope, critical for maintaining competitive advantage in this burgeoning field.
- Strategic positioning in South Korea's biotech ecosystem offers significant commercial potential amid rising global demand for natural, bioavailable health ingredients.
- Robust IP management requires vigilant monitoring of international filings, considering overlapping patents, and ensuring clear licensing pathways for commercial deployment.
FAQs
1. What distinguishes KR101562627 from prior beta-glucan patents?
KR101562627 uniquely emphasizes a specific nanoparticle manufacturing process from oat bran, including detailed process conditions and targeted applications, setting it apart from earlier, more generic extraction patents.
2. Can this patent be applied to produce beta-glucan nanoparticles from sources other than oat bran?
The claims focus specifically on oat bran-based extraction. Producing similar nanoparticles from other sources would require assessing whether the patent claims extend to alternative raw materials or if separate patents cover those methods.
3. What are the commercial prospects of beta-glucan nanoparticle products protected by this patent?
High, considering the growing consumer demand for natural immune-enhancing ingredients and the patent’s coverage over both nutraceuticals and pharmaceuticals employing these nanoparticles.
4. How does this patent influence competing players in the field?
It provides a strategic IP barrier that compels competitors to design around its process claims, potentially spurring innovation in alternative extraction or formulation methods.
5. What future legal developments should patent holders monitor?
Monitor international filings, potential patent litigations, or oppositions in Korea and abroad that may challenge the patent’s scope or validity, especially as the field evolves rapidly.
References:
[1] Korean Intellectual Property Office (KIPO). Patent KR101562627.
[2] WO2014/089123 A1. International patent application related to beta-glucan nanoparticles.
[3] Kim, J., & Lee, S. (2022). Advances in beta-glucan nanotechnology: Current trends and patent landscape. Journal of Functional Foods.
